Skip to content

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
***Poster 5 Pre-assessment***

Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials? (Required.)
2.What is your specialty?
3.How confident are you in the management of patients with ALL in your practice?
Very confident
Confident
Neutral
Little confidence
No confidence
4.Which of the following is best describes outcomes associated with addition of 1 cycle of nelarabine in adults with ALL based on the UKALL14 study? (Required.)
5.An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCRg deletion (ABD) were associated with which of the following outcomes?(Required.)
6.Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of first-line therapy on the GRAAPH 2014 protocol for Philadelphia chromosome positive acute lymphoblastic leukemia is associated with:(Required.)
7.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 
Privacy & Cookie Notice